别名 Biferonex、HSA-free IFN β-1a、Interferon beta-1a 靶点 IFNAR 作用机制 IFNAR激动剂(干扰素α/β受体复合体激动剂)、免疫调节剂 治疗领域 免疫系统疾病神经系统疾病其他疾病 在研适应症- 非在研适应症 多发性硬化症 原研机构 Rentschler Biotechnologie GmbH 在研机构- 非在研机构 Biopartners GmbHRentschl...
药物总览提供了干扰素β-1a (Biogen)Interferon beta-1a (Biogen)相关药品信息, 涵盖了药品临床前,临床阶段,注册,上市等药品全生命周期研发数据, 通过表格与图表等形式多维度地帮助帮助用户筛选与查看
Interferon-beta 1a is a prescription medication used to treat the symptoms ofMultiple Sclerosis. Interferon-beta 1a is available under the following different brand names: Avonex, Rebif, Rebif Rebidose, AVOSTARTGRIP What Are Side Effects Associated with Using Interferon beta 1a? Common side effects...
药物总览提供了干扰素β-1a (Merck Serono)Interferon beta-1a (Merck Serono)相关药品信息, 涵盖了药品临床前,临床阶段,注册,上市等药品全生命周期研发数据, 通过表格与图表等形式多维度地帮助帮助用户筛选与查看
New Drug Checklist: Interferon Beta-1AInterferon beta-1A treats multiple sclerosis.Anonymous
Avonex is not recommended for use during pregnancy. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding. Additional Information Our Avonex (Interferon beta-1a) Side Effects Drug Center provides a comprehensive view of available drug information on the potentia...
Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study BACKGROUND: Subcutaneous pegylated interferon (peginterferon) beta-1a is being developed for treatment of relapsing multiple sclerosis, with less frequent dosing than currently availab...
Avonex - Interferon beta-1a - Medical DrugVirtual Medical Centre Com
Drug Profile Interferon beta-1a - Merck Serono Alternative Names: Interferon β-1a - Merck Serono; r-IFNβ-1a; Rebif; Rebif Rebidose; Rebif® modified formulation; Rebif® New Formulation; Rebif® reformulation; Rebif® Serum-free formulation; Recombinant human interferon beta-1a; RNF ...
NSC: No significant change; GA: Glatiramer Acetate; NTZ: Natalizumab; MTX: Mitoxantrone; FGL: Fingolimod; INF-B: Interferon Beta; TRF: Teriflunomide; D: Drug recipients; C: Controls The efficacy of influenzavaccinationin patients affected byMSand treated with beta-interferon was assessed in three...